Brokerages Anticipate AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Will Announce Earnings of -$0.06 Per Share

Wall Street brokerages forecast that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will announce earnings of ($0.06) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for AVEO Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.05). AVEO Pharmaceuticals posted earnings per share of ($0.15) in the same quarter last year, which indicates a positive year-over-year growth rate of 60%. The business is expected to issue its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that AVEO Pharmaceuticals will report full year earnings of ($0.16) per share for the current year, with EPS estimates ranging from ($0.21) to ($0.11). For the next financial year, analysts expect that the company will report earnings of ($0.15) per share, with EPS estimates ranging from ($0.18) to ($0.10). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.74 million. AVEO Pharmaceuticals had a negative return on equity of 24.50% and a net margin of 70.30%.

Several equities research analysts have issued reports on the stock. National Securities reissued a “sell” rating and issued a $5.00 price target on shares of Oxford Square Capital in a report on Thursday, March 28th. HC Wainwright reissued a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Monday, March 18th. Finally, Zacks Investment Research lowered shares of HEXO from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company’s stock. AVEO Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $1.96.

Hedge funds have recently made changes to their positions in the company. Two Sigma Securities LLC bought a new stake in AVEO Pharmaceuticals during the fourth quarter worth approximately $28,000. HCR Wealth Advisors acquired a new stake in shares of AVEO Pharmaceuticals during the 1st quarter valued at about $28,000. Excalibur Management Corp grew its position in shares of AVEO Pharmaceuticals by 363.6% during the 1st quarter. Excalibur Management Corp now owns 51,000 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 40,000 shares during the period. SG Americas Securities LLC acquired a new stake in shares of AVEO Pharmaceuticals during the 1st quarter valued at about $50,000. Finally, Rhumbline Advisers grew its position in shares of AVEO Pharmaceuticals by 50.4% during the 4th quarter. Rhumbline Advisers now owns 138,271 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 46,307 shares during the period. 28.31% of the stock is currently owned by hedge funds and other institutional investors.

AVEO Pharmaceuticals stock traded down $0.01 on Friday, hitting $0.70. The company’s stock had a trading volume of 99,774 shares, compared to its average volume of 2,679,862. The stock has a market capitalization of $115.67 million, a price-to-earnings ratio of -3.68 and a beta of 0.88. The firm has a fifty day simple moving average of $0.72. AVEO Pharmaceuticals has a one year low of $0.49 and a one year high of $3.59.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Article: Asset Allocation

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.